A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after a third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in Circulation.
…
in Health
Data from Israel: Myocarditis after COVID-19 vaccines remain rare, highest risk in young males
